North America RSV Diagnostics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)
North America RSV Diagnostics Market: by Type (Rapid Antigen Detection Tests, Molecular Diagnostics, Immunoassays, Chromatography, Others), Application (Hospitals, Clinics, Laboratories, Home Care, Research Institutes, Others), Distribution Channels (Direct Sales, Distributors, Online, Pharmacies, Retail Stores, Others), Technology (PCR, Immunofluorescence Assay, Enzyme-Linked Immunosorbent Assay, Lateral Flow Immunoassay, Biosensors, Others), Organization Size (Small, Medium, Large) and By North America Historical & Forecast Period (2020-2035) Comprehensive Study 2025
Last Updated: 31-07-2025 | Format: PDF | Report ID:20322 | Author: Lily
North America RSV Diagnostics Market Insights, 2025-2035
The North America RSV Diagnostics Market is set to experience robust growth from 2025 to 2035, driven by advancements in diagnostic technologies and the increasing prevalence of respiratory syncytial virus (RSV) infections. The ongoing demand for rapid and accurate detection methods in healthcare settings and among home care users is reshaping market dynamics. Cutting-edge platforms, regulatory developments, and strategic partnerships continue to enhance accessibility and efficiency in RSV detection. The industry features fierce competition among leading vendors, supported by innovations in PCR, immunofluorescence, and biosensor technologies.
Latest Market Dynamics
Key Drivers
Rising incidence of RSV infections across North America is boosting demand for diagnostics as hospitals and laboratories prioritize early detection. Abbott Laboratories recently reported increased RSV test volumes in clinics for the 2024-2025 season, spotlighting the disease’s growing public health impact.
Growing adoption of advanced molecular diagnostics, such as PCR and multiplex assays, is catalyzing accurate and early detection of RSV. In March 2024, Thermo Fisher Scientific expanded its product portfolio with new high-sensitivity molecular RSV tests for point-of-care use, highlighting this trend.
Key Trends
Integration of AI-powered analytics and digital connectivity to diagnostic platforms is trending, enabling real-time surveillance and remote RSV diagnosis. Siemens Healthineers has piloted cloud-connected RSV test readers in select US health systems in 2024.
Increased penetration of home-based diagnostic kits as consumers seek convenience and faster results. QuidelOrtho Corporation launched an OTC RSV test in April 2024, expanding direct-to-consumer accessibility and supporting decentralized care.
Key Opportunities
Expansion into home care and telemedicine markets presents a significant growth avenue, with partnerships between diagnostic vendors and telehealth providers. Hologic, Inc. announced a collaboration with Teladoc Health in June 2024 to bundle RSV self-test kits with virtual care services.
Rising governmental and institutional investments in RSV surveillance programs in Canada and the US offer opportunities to scale diagnostic solutions. In July 2024, Danaher Corporation was awarded new contracts from Canadian health authorities for broad RSV screening initiatives.
Key Challenges
Ensuring accuracy and minimizing false negatives or positives in rapid RSV tests remain a key challenge, especially for home-use solutions. Recent evaluations by CDC in 2024 found variability in sensitivity among lateral flow tests from several manufacturers.
Supply chain disruptions and logistical issues impacting timely delivery of diagnostic kits, especially during seasonal RSV surges. In early 2024, Becton, Dickinson and Company faced backorders for RSV rapid tests due to increased demand and transport delays.
Key Restraints
High cost of advanced molecular diagnostic instruments and maintenance constrains adoption, particularly for small and medium organizations. Luminex Corporation noted lower uptake among clinics with limited budgets for new PCR systems in Q2 2024.
Stringent regulatory approval processes and evolving compliance requirements delay the market entry of novel RSV diagnostic tests. GenMark Diagnostics, Inc. referenced regulatory holdups for its multiplex assay launch in both the US and Canada.
The RSV diagnostics market in North America will experience segmental growth led by molecular diagnostics, rapid antigen detection tests, and immunoassays. With molecular diagnostics offering unparalleled accuracy, there is a notable shift away from conventional rapid antigen detection. Rapid antigen tests maintain strong presence due to their speed and affordability, while immunoassays provide high specificity in clinical laboratory settings. Chromatography and biosensors, though more niche, are gaining momentum through investments in innovation and improved detection capabilities. The evolving disease landscape, coupled with continuous technological improvements, is shaping the competitive dynamics among these types.
Hospitals dominate the RSV diagnostics market application landscape in North America for 2025, driven by centralized testing, broader access to advanced technologies, and the critical need for timely infection management in acute care. Laboratories command a significant share due to their role in confirmatory testing and surveillance, while clinics are emerging as vital points for RSV screening, especially among pediatric and vulnerable adult populations. Home care and research institutes contribute notably with the growing adoption of self-administered tests and ongoing public health studies. This distribution underscores the market's shift toward diversified application and patient-centric diagnostics.
From 2020 to 2035, the North America RSV diagnostics market is projected to significantly increase in revenue, fueled by growing public health initiatives, investments in next-generation testing, and broader laboratory and community healthcare access. Starting at approximately $800 million in 2021, the market is forecasted to surpass $2,500 million by 2035. The rollout of advanced molecular diagnostics, home-based kits, and multiplex platforms is accelerating revenue growth, particularly as organizations scale up testing following seasonal and pandemic surges. Sustained innovation and regulatory support will further empower market expansion across the forecast period.
Year-over-year (YOY) growth rates in the North America RSV diagnostics market reflect consistent upward momentum, averaging 8–12% annually from 2020 to 2035. Peak YOY spikes align with heightened RSV outbreaks and rapid test technology launches, notably in 2025 (12.5%) and post-pandemic periods with greater diagnostic adoption. Growth moderates toward 2035 as market penetration stabilizes, diagnostic infrastructure matures, and competitive intensity rises. The pattern highlights how seasonal health events, innovation cycles, and macroeconomic factors interplay in shaping diagnostic market expansion.
The United States leads the North America RSV diagnostics market by region, accounting for the vast majority of test volumes and revenue due to its advanced healthcare infrastructure, large population base, and proactive infection control policies. Canada holds a substantial share, benefiting from government-driven RSV surveillance and public funding for diagnostic expansion. Mexico, while relatively smaller in share, shows rapid market uptake in urban centers and improved access to rapid testing solutions. The regional split underscores both the maturity of established markets and the growth potential in emerging areas within North America.
In 2025, the North America RSV diagnostics landscape remains highly consolidated, with leading players like Abbott Laboratories, Becton Dickinson, and QuidelOrtho Corporation controlling the majority of market share. These companies leverage robust research capabilities, wide distribution networks, and strong product portfolios. New entrants and smaller innovators target niche applications or disruptive technologies, but incumbents maintain dominance through scale and regulatory leadership. Market competitiveness is further sharpened by ongoing product launches, strategic acquisitions, and investments in next-gen molecular and point-of-care diagnostic solutions.
Hospitals and healthcare systems constitute the largest buyer segment for RSV diagnostics in North America in 2025, emphasizing their central role in large-scale and high-frequency testing. Clinical laboratories and reference labs follow closely, undertaking confirmatory and surveillance testing, while retail and clinic buyers gain momentum through decentralized care models. Home care providers and individuals also comprise a growing share, mirroring trends in self-testing and consumer-driven healthcare. This buyer distribution highlights the expanding reach and flexible adoption of RSV diagnostic solutions within varied care environments.
Study Coverage
Metrics
Details
Years
2020-2035
Base Year
2025
Market Size
1020
Regions
United States, Canada, Mexico
Segments
Rapid Antigen Detection Tests, Molecular Diagnostics, Immunoassays, Chromatography, Others, Hospitals, Clinics, Laboratories, Home Care, Research Institutes, Others, Direct Sales, Distributors, Online, Pharmacies, Retail Stores, Others, PCR, Immunofluorescence Assay, Enzyme-Linked Immunosorbent Assay, Lateral Flow Immunoassay, Biosensors, Others, Small, Medium, Large
June 2024: Thermo Fisher Scientific introduced a high-throughput RSV molecular assay for hospital laboratories across the US and Canada.
July 2024: Danaher Corporation secured a multi-year contract with Canadian provincial health systems for RSV surveillance program kits.
July 2024: Hologic, Inc. announced a strategic partnership with Teladoc Health to provide bundled RSV self-test kits and virtual consultations.
August 2024: QuidelOrtho Corporation launched an over-the-counter RSV rapid antigen test in major US retail channels.
August 2024: Siemens Healthineers received FDA breakthrough designation for its AI-enabled RSV diagnostic platform.
Frequently Asked Questions
About the Author
Lily
Senior Market Research Analyst
Lily is a Senior Market Research Analyst specializing in market research, industry analysis, and business consulting across Healthcare. Lily brings a commercially grounded perspective to sectors shaped by changing demand, innovation, and competitive dynamics, helping turn complex market trends into clear strategic insights for business decision-makers. With 10+ years of experience across research, analytics, and strategic advisory roles, Lily has helped organizations translate data into actionable growth strategies.
